OmniAb lifts FY26 cash guidance; signs Eli Lilly ion-channel deal
OmniAb shares rise after the company revised its FY26 Cash and Cash Equivalent guidance above prior expectations and announced a global collaboration and license agreement with Eli Lilly for a new ion channel program.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.